Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors

A north central cancer treatment group trial

Susan K. Quella, Charles L. Loprinzi, Debra L. Barton, James A. Knost, Jeff A. Sloan, Beth I. LaVasseur, Debra Swan, Kenneth R. Krupp, Kathy Miller, Paul J. Novotny

Research output: Contribution to journalArticle

342 Citations (Scopus)

Abstract

Purpose: Hot flashes represent a significant clinical problem for some breast cancer survivors. Safe, effective treatment is needed for this prominent clinical problem. Although it has been shown that estrogen or progesterone replacement therapy can alleviate this problem, there are continued safety concerns regarding the use of hormonal therapies in these women. Based on anecdotal information, we hypothesized that soy-derived phytoestrogens, weak estrogen-like substances in the soybean that demonstrate estrogen agonist and/or antagonist effects when they bind to estrogen receptors, could alleviate hot flashes. This current trial was designed to investigate this hypothesis. Patients and Methods: This double-blind clinical trial involved breast cancer survivors with substantial hot flashes. After randomization, patients underwent a 1-week baseline period with no therapy. This was followed by 4 weeks of either soy tablets or placebo. The patients then crossed over to the opposite arm in a double-blind manner for the last 4 weeks. Patients completed a daily questionnaire documenting hot flash frequency, intensity, and perceived side effects. Results: Of the 177 women who were randomized and started the study substance, 155 (88%) provided useable data over the first 5 weeks; 149 provided usable data over the entire 9 weeks. There was no suggestion that the soy product was more effective in reducing hot flashes than the placebo. At study completion, patients preferred the soy product 33% of the time, the placebo 37% of the time, and neither substance 31% of the time. No toxicity was observed. Conclusion: The soy product did not alleviate hot flashes in breast cancer survivors. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish (US)
Pages (from-to)1068-1074
Number of pages7
JournalJournal of Clinical Oncology
Volume18
Issue number5
StatePublished - Mar 2000
Externally publishedYes

Fingerprint

Hot Flashes
Phytoestrogens
Survivors
Breast Neoplasms
Neoplasms
Estrogens
Placebos
Therapeutics
Random Allocation
Soybeans
Double-Blind Method
Estrogen Receptors
Tablets
Progesterone
Clinical Trials
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Quella, S. K., Loprinzi, C. L., Barton, D. L., Knost, J. A., Sloan, J. A., LaVasseur, B. I., ... Novotny, P. J. (2000). Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A north central cancer treatment group trial. Journal of Clinical Oncology, 18(5), 1068-1074.

Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors : A north central cancer treatment group trial. / Quella, Susan K.; Loprinzi, Charles L.; Barton, Debra L.; Knost, James A.; Sloan, Jeff A.; LaVasseur, Beth I.; Swan, Debra; Krupp, Kenneth R.; Miller, Kathy; Novotny, Paul J.

In: Journal of Clinical Oncology, Vol. 18, No. 5, 03.2000, p. 1068-1074.

Research output: Contribution to journalArticle

Quella, SK, Loprinzi, CL, Barton, DL, Knost, JA, Sloan, JA, LaVasseur, BI, Swan, D, Krupp, KR, Miller, K & Novotny, PJ 2000, 'Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A north central cancer treatment group trial', Journal of Clinical Oncology, vol. 18, no. 5, pp. 1068-1074.
Quella, Susan K. ; Loprinzi, Charles L. ; Barton, Debra L. ; Knost, James A. ; Sloan, Jeff A. ; LaVasseur, Beth I. ; Swan, Debra ; Krupp, Kenneth R. ; Miller, Kathy ; Novotny, Paul J. / Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors : A north central cancer treatment group trial. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 5. pp. 1068-1074.
@article{5fd1d2ac5c6c4c5fbab461ec457ea82b,
title = "Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A north central cancer treatment group trial",
abstract = "Purpose: Hot flashes represent a significant clinical problem for some breast cancer survivors. Safe, effective treatment is needed for this prominent clinical problem. Although it has been shown that estrogen or progesterone replacement therapy can alleviate this problem, there are continued safety concerns regarding the use of hormonal therapies in these women. Based on anecdotal information, we hypothesized that soy-derived phytoestrogens, weak estrogen-like substances in the soybean that demonstrate estrogen agonist and/or antagonist effects when they bind to estrogen receptors, could alleviate hot flashes. This current trial was designed to investigate this hypothesis. Patients and Methods: This double-blind clinical trial involved breast cancer survivors with substantial hot flashes. After randomization, patients underwent a 1-week baseline period with no therapy. This was followed by 4 weeks of either soy tablets or placebo. The patients then crossed over to the opposite arm in a double-blind manner for the last 4 weeks. Patients completed a daily questionnaire documenting hot flash frequency, intensity, and perceived side effects. Results: Of the 177 women who were randomized and started the study substance, 155 (88{\%}) provided useable data over the first 5 weeks; 149 provided usable data over the entire 9 weeks. There was no suggestion that the soy product was more effective in reducing hot flashes than the placebo. At study completion, patients preferred the soy product 33{\%} of the time, the placebo 37{\%} of the time, and neither substance 31{\%} of the time. No toxicity was observed. Conclusion: The soy product did not alleviate hot flashes in breast cancer survivors. (C) 2000 by American Society of Clinical Oncology.",
author = "Quella, {Susan K.} and Loprinzi, {Charles L.} and Barton, {Debra L.} and Knost, {James A.} and Sloan, {Jeff A.} and LaVasseur, {Beth I.} and Debra Swan and Krupp, {Kenneth R.} and Kathy Miller and Novotny, {Paul J.}",
year = "2000",
month = "3",
language = "English (US)",
volume = "18",
pages = "1068--1074",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors

T2 - A north central cancer treatment group trial

AU - Quella, Susan K.

AU - Loprinzi, Charles L.

AU - Barton, Debra L.

AU - Knost, James A.

AU - Sloan, Jeff A.

AU - LaVasseur, Beth I.

AU - Swan, Debra

AU - Krupp, Kenneth R.

AU - Miller, Kathy

AU - Novotny, Paul J.

PY - 2000/3

Y1 - 2000/3

N2 - Purpose: Hot flashes represent a significant clinical problem for some breast cancer survivors. Safe, effective treatment is needed for this prominent clinical problem. Although it has been shown that estrogen or progesterone replacement therapy can alleviate this problem, there are continued safety concerns regarding the use of hormonal therapies in these women. Based on anecdotal information, we hypothesized that soy-derived phytoestrogens, weak estrogen-like substances in the soybean that demonstrate estrogen agonist and/or antagonist effects when they bind to estrogen receptors, could alleviate hot flashes. This current trial was designed to investigate this hypothesis. Patients and Methods: This double-blind clinical trial involved breast cancer survivors with substantial hot flashes. After randomization, patients underwent a 1-week baseline period with no therapy. This was followed by 4 weeks of either soy tablets or placebo. The patients then crossed over to the opposite arm in a double-blind manner for the last 4 weeks. Patients completed a daily questionnaire documenting hot flash frequency, intensity, and perceived side effects. Results: Of the 177 women who were randomized and started the study substance, 155 (88%) provided useable data over the first 5 weeks; 149 provided usable data over the entire 9 weeks. There was no suggestion that the soy product was more effective in reducing hot flashes than the placebo. At study completion, patients preferred the soy product 33% of the time, the placebo 37% of the time, and neither substance 31% of the time. No toxicity was observed. Conclusion: The soy product did not alleviate hot flashes in breast cancer survivors. (C) 2000 by American Society of Clinical Oncology.

AB - Purpose: Hot flashes represent a significant clinical problem for some breast cancer survivors. Safe, effective treatment is needed for this prominent clinical problem. Although it has been shown that estrogen or progesterone replacement therapy can alleviate this problem, there are continued safety concerns regarding the use of hormonal therapies in these women. Based on anecdotal information, we hypothesized that soy-derived phytoestrogens, weak estrogen-like substances in the soybean that demonstrate estrogen agonist and/or antagonist effects when they bind to estrogen receptors, could alleviate hot flashes. This current trial was designed to investigate this hypothesis. Patients and Methods: This double-blind clinical trial involved breast cancer survivors with substantial hot flashes. After randomization, patients underwent a 1-week baseline period with no therapy. This was followed by 4 weeks of either soy tablets or placebo. The patients then crossed over to the opposite arm in a double-blind manner for the last 4 weeks. Patients completed a daily questionnaire documenting hot flash frequency, intensity, and perceived side effects. Results: Of the 177 women who were randomized and started the study substance, 155 (88%) provided useable data over the first 5 weeks; 149 provided usable data over the entire 9 weeks. There was no suggestion that the soy product was more effective in reducing hot flashes than the placebo. At study completion, patients preferred the soy product 33% of the time, the placebo 37% of the time, and neither substance 31% of the time. No toxicity was observed. Conclusion: The soy product did not alleviate hot flashes in breast cancer survivors. (C) 2000 by American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=17544401532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17544401532&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 1068

EP - 1074

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -